CTI BioPharma Corp. (NASDAQ: CTIC) is -21.12% lower on its value in year-to-date trading and has touched a low of $0.86 and a high of $4.13 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CTIC stock was last observed hovering at around $2.91 in the last trading session, with the day’s loss setting it -0.37% off its average median price target of $6.90 for the next 12 months. It is also 80.46% off the consensus price target high of $13.00 offered by 4 analysts, but current levels are 36.5% higher than the price target low of $4.00 for the same period.
Currently trading at $2.54, the stock is -17.41% and -21.64% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 10.77 million and changing -12.71% at the moment leaves the stock 0.17% off its SMA200. CTIC registered 173.12% gain for a year compared to 6-month gain of 18.14%. The firm has a 50-day simple moving average (SMA 50) of $3.1300 and a 200-day simple moving average (SMA200) of $3.1211.
The stock witnessed a -21.85% loss in the last 1 month and extending the period to 3 months gives it a -21.85%, and is -9.29% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.56% over the week and 8.77% over the month.
Distance from 52-week low is 195.35% and -38.50% from its 52-week high.
CTI BioPharma Corp. (CTIC) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for CTI BioPharma Corp. (CTIC) is a “Buy”. 4 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 4 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
CTI BioPharma Corp. is expected to release its quarterly report on 08/05/2021 and quarterly earnings per share for the current quarter are estimated at -$0.23.The EPS is expected to shrink by -6.80% this year.
CTI BioPharma Corp. (CTIC) Top Institutional Holders
77 institutions hold shares in CTI BioPharma Corp. (CTIC), with 193.24k shares held by insiders accounting for 0.25% while institutional investors hold 59.74% of the company’s shares. The shares outstanding are 74.67M, and float is at 54.89M with Short Float at 0.73%. Institutions hold 59.59% of the Float.
The top institutional shareholder in the company is Orbimed Advisors LLC. with over 9.52 million shares valued at $30.66 million. The investor’s holdings represent 12.41% of the CTIC Shares outstanding. As of Dec 30, 2020, the second largest holder is NEA Management Company, LLC with 7.14 million shares valued at $22.99 million to account for 9.31% of the shares outstanding. The other top investors are BVF Inc. which holds 6.93 million shares representing 9.04% and valued at over $22.31 million, while Caxton Corp holds 4.89% of the shares totaling 3.75 million with a market value of $12.07 million.
CTI BioPharma Corp. (CTIC) Insider Activity
A total of 1 insider transactions have happened at CTI BioPharma Corp. (CTIC) in the last six months, with sales accounting for 1 and purchases happening 0 times. The most recent transaction is an insider sale by ORBIMED ADVISORS LLC ,the company’s10% Owner. SEC filings show that ORBIMED ADVISORS LLC sold 2,000,000 shares of the company’s common stock on Jan 07 at a price of $3.50 per share for a total of $7.0 million. Following the sale, the insider now owns 7.52 million shares.
CTI BioPharma Corp. (CTIC): Who are the competitors?
The company’s main competitors (and peers) include Eli Lilly and Company (LLY) that is trading 35.79% up over the past 12 months and Madrigal Pharmaceuticals Inc. (MDGL) that is 96.78% higher over the same period. Bristol-Myers Squibb Company (BMY) is 14.79% up on the 1-year trading charts. Short interest in the company’s stock has risen 5.9% from the last report on Feb 11, 2021 to stand at a total of 0.38 million short shares sold with a short interest ratio of 0.79.